OR WAIT null SECS
Becton Dickinson’s (BD) Advanced Bioprocessing business will be integrated into Thermo Fisher's Life Sciences Solutions segment.
Thermo Fisher Scientific announced on Sept. 7, 2018 that it has signed a definitive agreement with Becton Dickinson (BD), a global medical technology company, under which Thermo Fisher will acquire BD's Advanced Bioprocessing business.
The business combines a technical services program with a variety of peptones that enhance cell-culture media formulations to improve yield and reduce variability in biopharmaceutical applications. Thermo Fisher reports that BD's Advanced Bioprocessing business has annualized revenue of approximately $100 million and will be integrated into Thermo Fisher's Life Sciences Solutions segment. The transaction is subject to customary closing conditions and is expected to close in early 2019.
"The addition of these new capabilities will complement our bioproduction offering and strengthen our ability to serve this rapidly growing market, from development to large-scale production," said Mark Stevenson, executive vice-president and chief operating officer of Thermo Fisher Scientific, in a company press release.
Source: Thermo Fisher Scientific